Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat + Rituximab in R/R Follicular Lymphoma
NCT04762160Phase 2Terminated
- Sponsor
- Epizyme, Inc.
- Start
- Dec 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tazemetostat in follicular lymphoma (FL), sponsored by Epizyme, Inc.. Started Dec 2020; status: terminated.
02
Drugs
tazemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04762160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762160.